Non-Hodgkin Lymphoma Diagnostics Market to Observe Prominent CAGR Growth of 8.5% by 2030
Global Non-Hodgkin Lymphoma Diagnostics Market research report makes use of SWOT analysis and Porter’s Five Forces analysis to disclose the strengths, weaknesses, opportunities, and threats in the HELATH industry. This report is an important source of guidance for companies and individuals offering industry chain structure, business strategies and proposals for new project investments. Analysis and estimation of important industry trends, market size, and market share are mentioned in this market report. An influential Global Non-Hodgkin Lymphoma Diagnostics Market business report proves to be an indispensable document for every market enthusiast, policymaker, investor, and player.
The non-Hodgkin’s lymphoma is a general category of lymphoma. There are many subtypes that fall into this category. Diffuse large B-cell lymphoma and follicular lymphoma are among the most common subtypes. The other general category of lymphoma is Hodgkin lymphoma. Advances in the diagnosis and treatment of non-Hodgkin lymphoma have helped improve the prognosis for people with this disease.
The global non-Hodgkin lymphoma diagnostics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the global non-Hodgkin lymphoma diagnostics market will grow at a CAGR of 8.5% during the forecast period of 2023 to 2030.
Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-non-hodgkin-lymphoma-diagnostics-market&Shri
The global non-Hodgkin lymphoma diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing research in the field of non-Hodgkin lymphoma diagnosis and development is further boosting the market growth. However, difficulties in non-Hodgkin lymphoma screening techniques might hamper the growth of the global non-Hodgkin lymphoma diagnostics market in the forecast period.
Cancer begins in the lymphs and most often occurs in people who smoke. Two major types of non-Hodgkin lymphoma are aggressive non-Hodgkin lymphoma and indolent non-Hodgkin lymphoma. Causes of non-Hodgkin lymphoma include smoking, second-hand smoke, exposure to certain toxins, and family history.
Symptoms include a cough (often with blood), chest pain, wheezing, and weight loss. These symptoms often don’t appear until the cancer is advanced. Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy.
Fundamental Aim of this Market Report
- Factors influencing This Market Size and growth rate.
- Major alterations to this market in the near future.
- Notable Market rivals around the world.
- Future Scope and Product Outlook
- Future-promising emerging markets.
- The Market Presents Difficult Challenges and Threats.
Key Findings of the Study
- Advancement in artificial intelligence in the diagnosis of non-Hodgkin lymphoma is expected to drive the market growth
- The imaging test type segment is expected to grow because of easy adaptability and low cost of implementation
- An increase in awareness regarding non-Hodgkin lymphoma acting as a major driver for the demand for non-Hodgkin lymphoma diagnosis
- Technological advancements and rising government funded projects for healthcare infrastructure are expected to drive the market growth
RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
Preventive health check-up is preventive actions performed for the initial detection of cancer disease, and also rising preference for preventive health check-ups provide a safeguard against likely exposure to any disease in the future.
Awareness to promote screening is the most important component of cancer prevention. The check-up is comprised of the identification of cancer and examinations of risk factors to limit loss at an early stage.
Preventive cancer check-up is performed with the help of various diagnostic tests, including ultrasound, biopsy, immunohistochemistry, antibody test, and blood test (TSH, T3, T4, and TSI), among others.
Furthermore, these days the demand for preventive cancer diagnostics has increased due to increasing concern toward the disease non-Hodgkin lymphoma in the population worldwide, which boosts the demand in the global non-Hodgkin lymphoma diagnostics market
Market Developments
- In November 2022, Danaher announced that it had entered a strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation. The program invests in product innovation to advance external R&D strategies with a focus on genomic medicines, precision diagnostics, next-generation bio manufacturing, human systems, and data sciences
- In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics, a Poland-based developer of innovative technology solutions for the medical diagnostic and healthcare markets. This has helped the company to increase its product portfolio and global presence in the market
- In June 2022, Agilent Technologies Inc. announced that previously CE-IVD marked instruments, kits, and reagents were released as IVDR Class A on May 26, 2022, in compliance with the new EU IVDR regulation
- In March 2021, Hologic, Inc. announced that the company had acquired Diagenode, a privately held European developer and manufacturer of molecular diagnostic assays and epigenetics products. This further strengthens the molecular diagnostics business in the global market
- In August 2020, Siemens Healthcare GmbH entered into an agreement with Varian Medical Systems, Inc. With this acquisition, Siemens Healthcare has helped in developing advanced solutions to treat cancer and strengthen its position in the healthcare industry
To Gain More Insights into the Market Analysis, Browse the Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-non-hodgkin-lymphoma-diagnostics-market?Shri
Major Players
Data Bridge Market Research recognizes the following companies as the major market players in the Global Non-Hodgkin Lymphoma Diagnostics market. They are CANON MEDICAL SYSTEMS CORPORATION, Koninklijke Philips N.V., Siemens Healthcare GmbH, Danaher., Bio-Rad Laboratories, Inc., General Electric Company, Sysmex Corporation, Grail, F. Hoffmann-La Roche, Neusoft Corporation, Agilent Technologies, Inc., NeoGenomics Laboratories, Hologic, Inc, Integrated DNA Technologies, Inc., CENTOGENE N.V., Merit Medical Systems, Invitae Corporation, PerkinElmer Inc., QIAGEN, and GeneDx, LLC among others
Segment Analysis:
The global non-Hodgkin lymphoma diagnostics market is categorized into eight notable segments, which are based on the test type, cancer stage, tumor type, product, technology, application, end users, and distribution channel
On the basis of test type, the global non-Hodgkin lymphoma diagnostics market is segmented into imaging, biopsy, immunohistochemistry, biomarker test, genetic test, cytogenetics, lumbar puncture (spinal tap), blood test, cytochemistry, and others.
In 2023, the imaging segment is expected to dominate the market due to the primary test recommended for preliminary testing
In 2023, the imaging segment is expected to dominate the market due to the primary test recommended for preliminary testing. The imaging segment is expected to reach the highest CAGR of 11.2% in the forecast period of 2023-2030.
- On the basis of test type, the global non-Hodgkin lymphoma diagnostics market is segmented into imaging, biopsy, immunohistochemistry, biomarker test, genetic test, cytogenetics, lumbar puncture (spinal tap), blood test, cytochemistry, and others. In 2023, the imaging segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market, as imaging is the primary test recommended for preliminary testing. As imaging looks for cancer in its early stages and a person has no symptoms
- On the basis of the cancer stage, the global non-Hodgkin lymphoma diagnostics market is segmented into stage 0, I, II, III, and IV. In 2023, the stage IV segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market as the cancer stage tells where a cancer is located and its size and how far it has grown into nearby tissues. The clinical stage is an estimate of the extent of cancer based on the results of diagnostics
- On the basis of tumor type, the global non-Hodgkin lymphoma diagnostics market is segmented into aggressive lymphomas and indolent lymphomas. In 2023, the aggressive lymphomas segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market as it is a rare type of non-Hodgkin lymphoma and is a high-grade lymphoma that affects blood cells called T cells
- On the basis of product, the global non-Hodgkin lymphoma diagnostics market is segmented into instrument based products, platform based products, kits and reagents, and other consumables. In 2023, the instrument based products segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market due to increasing technical advancements in non-Hodgkin lymphoma diagnostics
- On the basis of technology, the global non-Hodgkin lymphoma diagnostics market is segmented into fluorescent in situ hybridization, next generation sequencing, fluor immunoassay, comparative genomic hybridization, immunohistochemically, and others. In 2023, the fluorescent in situ hybridization segment is expected to dominate in the non-Hodgkin lymphoma diagnostics market as it is the most convincing technique for locating the specific DNA sequences, diagnosis of genetic diseases, gene mapping, and identification of novel oncogenes or genetic aberrations contributing to various types of cancers
- On the basis of application, the global non-Hodgkin lymphoma diagnostics market is segmented into screening, diagnostic and predictive, prognostic, and research. In 2023, the screening segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market as it is the most convincing technique used to find cancer in people who have no symptoms, and regular screening gives the best chance of finding cancer early when it’s small and before it has spread
- On the basis of end user, the global non-Hodgkin lymphoma diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and others.
In 2023, the hospitals segment is expected to hold the largest share of the end user segment in the global non-Hodgkin lymphoma diagnostics market.
In 2023, the hospitals segment is expected to dominate the market because hospitals enable the facilitation of robust, on-time, cost-effective, and high quality diagnostic care and services in a safe healthcare environment. The hospitals segment is expected to grow with a CAGR of 10.7% in the forecast period of 2023 to 2030.
- On the basis of distribution channel, the global non-Hodgkin lymphoma diagnostics market is segmented into direct tender, retail sales, and others. In 2023, the direct tender segment is expected to dominate the global non-Hodgkin lymphoma diagnostics market as they are the primary source of procurement of reagents, consumables, devices, and accessories by healthcare organizations and diagnostic labs. With the increasing cost of healthcare, healthcare providers are focusing on better services for customers and reducing the overall cost. The procurement of products through direct tender is highly cost effective for healthcare providers
Key highlights of this Market report:
- Growth rate
- Remuneration prediction
- Consumption graph
- Market concentration ratio
- Secondary industry competitors
- Competitive structure
- Major restraints
- Market drivers
- Regional bifurcation
- Competitive hierarchy
- Current market tendencies
- Market concentration analysis
What benefits does the DBMR study is going to provide?
- Latest industry influencing trends and development scenario
- Open up New Markets
- To Seize powerful market opportunities
- Key decision in planning and to further expand market share
- Identify Key Business Segments, Market proposition & Gap Analysis
- Assisting in allocating marketing investments
Table of Contents:
- Introduction
- Market Segmentation
- Executive Summary
- Premium Insights
- Market Regulations
- Market Overview
Continued…
Browse Detailed Summary of Research Report with TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-non-hodgkin-lymphoma-diagnostics-market&Shri
Key Benefits of the Report:
- This study presents the analytical depiction of this industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of this market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed this industry analysis based on competitive intensity and how the competition will take shape in the coming years.
Top DBMR Healthcare Reports:
https://www.databridgemarketresearch.com/reports/global-cardasil-treatment-market?Shri
https://www.databridgemarketresearch.com/reports/global-aestheticcosmetic-lasers-market?Shri
https://www.databridgemarketresearch.com/reports/global-yeast-infection-market?Shri
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com
